SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense volatility as investors weigh conflicting reports surrounding peace talks in the Strait of Hormuz, with community sentiment deeply polarized between bulls betting on continued AI-driven momentum and bears anticipating a geopolitical-triggered correction. Traders are actively debating whether recent diplomatic headlines are a temporary market manipulation tool or a precursor to sustained economic instability.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community debates the delayed 80th clinical event in its pivotal REGAL trial, with bulls interpreting the extended duration as a sign of efficacy and bears questioning trial integrity. Investors are closely monitoring potential acquisition catalysts and institutional short-interest metrics while speculating on the company's path toward commercialization or a high-premium buyout.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is experiencing significant momentum driven by growing commercial validation through partnerships like Volvo and FedEx, alongside aggressive volume and short-covering activity. The community is actively discussing the company's potential as a long-term leader in autonomous trucking, focusing on scaling infrastructure and overcoming industry-wide labor challenges.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors weigh significant gains driven by structural AI infrastructure demand against market volatility and shifting macroeconomic expectations following Federal Reserve commentary. While the community actively debates whether the current semiconductor rally represents a sustainable long-term shift or an overextended bubble, sentiment remains sharply divided between bulls highlighting data center momentum and bears emphasizing valuation concerns.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing a parabolic, sentiment-driven rally fueled by severe memory and NAND flash supply shortages and increasing demand from data center infrastructure. While bulls are celebrating consistent ATHs and rapid gains, the community is deeply polarized, with many retail traders debating whether the stock is undergoing a historic re-rating or forming a dangerous bubble reminiscent of the dot-com era.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is capturing investor attention as the market shifts focus toward the future of real-world AI and autonomous transportation, though community sentiment remains divided between long-term optimism for eVTOL technology and frustration over the company's lack of recent technical milestones like piloted transition flights. Discussions are currently dominated by debates over institutional activity, including recent adjustments to holdings by major funds, and the company's progress toward regulatory certification ahead of high-profile global events.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is experiencing significant momentum driven by growing optimism over its expansion into the weight-loss peptide market and positive analyst sentiment regarding its telehealth platform. Investors are actively debating the potential for a short squeeze as the stock reclaims key technical levels, though some remain cautious, pointing to historically volatile price patterns and ongoing discussions regarding regulatory hurdles.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Compass Pathways is trending as investors bet on the company's progress toward FDA approval for its psilocybin treatment, COMP360, which community members view as a highly effective, scalable alternative to existing antidepressants like Spravato. Discussions are heavily focused on the stock's potential for a significant re-rating, driven by its priority regulatory status, a strong cash position, and growing speculation about a possible acquisition by major pharmaceutical players.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing renewed investor interest driven by rising trading volume and community debates over its role in Japan's blockchain ecosystem, though skeptics remain focused on past price volatility and concerns regarding long-term utility. Despite polarized sentiment, the community is actively tracking technical support levels and speculating on potential institutional adoption in the IoT and data ownership sectors.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant community attention as investors await imminent Phase 3 VELA trial results, which are expected to demonstrate best-in-class efficacy for their lead asset. The community is actively discussing the potential for a major valuation rerating and intensified M&A interest, with many anticipating that positive clinical data will trigger a significant breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

John B. Sanfilippo & Son to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 10th & 11th in New York, NY

John B. Sanfilippo & Son (NASDAQ: JBSS) today announced management will present at the East Coast IDEAS Investor Conference on Thursday June 11, 2026 at The Westin Times Square in New York, NY. The Companys presentation is scheduled to begin at 9:55am ET and will hold investor meetings throughout...

John B. Sanfilippo & Son, Inc. Voluntarily Recalls Snack Mix Products Due to Possible Health Risk

As a follow up to the voluntary recall of dry milk powder by California Dairies, Inc. due to the potential presence of Salmonella, John B. Sanfilippo & Son, Inc. (Nasdaq: JBSS) (the Company) announced today that it is voluntarily recalling certain snack mix items listed below that were flavored...

Wall Street Zen Downgrades John B. Sanfilippo & Son (NASDAQ:JBSS) to Buy

Wall Street Zen cut John B. Sanfilippo & Son from a "strong-buy" rating to a "buy" rating in a research note on Saturday...

John B. Sanfilippo & Son Q3 Earnings Call Highlights

John B. Sanfilippo & Son (NASDAQ:JBSS) reported fiscal third-quarter 2026 results highlighted by record net sales growth driven primarily by higher pricing, while profitability declined year over...

Sanfilippo & Son (JBSS) Q3 Earnings and Revenues Surpass Estimates

John B. Sanfilippo (JBSS) delivered earnings and revenue surprises of +23.70% and +8.03%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

John B. Sanfilippo & Son (NASDAQ:JBSS) Releases Earnings Results, Beats Estimates By $0.27 EPS

John B. Sanfilippo & Son (NASDAQ:JBSS - Get Free Report) announced its earnings results on Wednesday. The company reported $1.43 EPS for the quarter, beating analysts' consensus estimates of $1.16 by...

John B. Sanfilippo & Son, Inc. Reports Fiscal 2026 Third Quarter Results

John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the Company) today announced financial results for its fiscal 2026 third quarter ended March 26, 2026. Third Quarter Summary Net sales increased $20.9...

John B. Sanfilippo & Son (JBSS) Projected to Post Quarterly Earnings on Wednesday

John B. Sanfilippo & Son (NASDAQ:JBSS) will be releasing its Q3 2026 earnings after the market closes on Wednesday, April 29. (View Earnings Report at...

Lamb Weston (LW) Q3 Earnings and Revenues Top Estimates

Lamb Weston (LW) delivered earnings and revenue surprises of +18.42% and +5.40%, respectively, for the quarter ended February 2026. Do the numbers hold clues to what lies ahead for the stock?

John B. Sanfilippo & Son, Inc. Declares $1.50 Per Share Special Dividend

John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the Company) today announced that its Board of Directors (the Board) declared a special cash dividend (the Special Dividend) of $1.50 per share on all...

John B. Sanfilippo & Son, Inc. engages in the processing and distribution of nuts and nut-related products. It offers peanuts, pecans, cashews, walnuts, almonds, and other nuts under the brands of Fisher, Orchard Valley Harvest, Squirrel Brand, and Southern Style Nuts. The company was founded by Gaspare Sanfilippo and John B. Sanfilippo in 1922 and is headquartered in Elgin, IL.

Sanfilippo (John B.) & Son, Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$1.29	--	--	N/A
Q3 '26	$1.16	$1.43	23.70%	BEAT
Q2 '26	$1.36	$1.53	12.67%	BEAT
Q1 '26	$1.28	$1.59	23.93%	BEAT
Q2 '25	--	$1.16	--	N/A

JBSSSanfilippo (John B.) & Son, Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '26

Historical Earnings

Latest JBSS News